ChatGPT:
A few companies have been working on inhibitors that target immunosuppression in the tumor microenvironment, particularly through immune checkpoint inhibitors or other novel pathways. Some of the leaders in this space include:
- **Merck** (with Keytruda, targeting PD-1)
- **Bristol-Myers Squibb** (with Opdivo and Yervoy, targeting PD-1/PD-L1 and CTLA-4)
- **AstraZeneca** (with Imfinzi, targeting PD-L1)
- **Genentech/Roche** (with Tecentriq, targeting PD-L1)
- **Novartis** (with research on inhibitors of TIM-3 and LAG-3)
They are exploring various inhibitors, both as monotherapies and in combination with existing treatments, to overcome immune evasion by tumors. If I had to guess which company has the most promising candidates for future trials, **Merck** or **Bristol-Myers Squibb** may be leading the charge based on their extensive pipelines and ongoing research in immuno-oncology.
Market Data 
Markets 
AI
